Sequoia Financial Advisors LLC decreased its stake in Ingevity Corporation (NYSE:NGVT - Free Report) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,021 shares of the company's stock after selling 5,175 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Ingevity were worth $389,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock worth $23,769,000 after acquiring an additional 454,579 shares in the last quarter. Simcoe Capital Management LLC purchased a new stake in shares of Ingevity in the first quarter worth $8,568,000. Nuveen LLC bought a new stake in shares of Ingevity during the 1st quarter valued at $4,228,000. Millennium Management LLC lifted its stake in shares of Ingevity by 8.0% during the 1st quarter. Millennium Management LLC now owns 1,226,189 shares of the company's stock valued at $48,545,000 after buying an additional 90,958 shares in the last quarter. Finally, Ancora Advisors LLC lifted its stake in shares of Ingevity by 100.2% during the 1st quarter. Ancora Advisors LLC now owns 176,610 shares of the company's stock valued at $6,992,000 after buying an additional 88,380 shares in the last quarter. 91.59% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
NGVT has been the subject of a number of analyst reports. Wall Street Zen upgraded Ingevity from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Ingevity in a report on Wednesday, October 8th. Wells Fargo & Company upped their price target on Ingevity from $38.00 to $48.00 and gave the stock an "equal weight" rating in a research note on Monday, July 14th. Finally, BMO Capital Markets lifted their price objective on shares of Ingevity from $62.00 to $68.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Ingevity currently has an average rating of "Hold" and an average target price of $58.00.
View Our Latest Stock Analysis on Ingevity
Ingevity Price Performance
Ingevity stock opened at $55.87 on Wednesday. Ingevity Corporation has a 52-week low of $28.49 and a 52-week high of $60.77. The company has a quick ratio of 0.80, a current ratio of 1.36 and a debt-to-equity ratio of 10.24. The firm's fifty day moving average is $56.22 and its 200 day moving average is $46.38. The company has a market cap of $2.04 billion, a price-to-earnings ratio of -9.39 and a beta of 1.40.
Ingevity (NYSE:NGVT - Get Free Report) last announced its earnings results on Friday, March 24th. The company reported $0.78 EPS for the quarter. The firm had revenue of $336.00 million during the quarter. Ingevity had a positive return on equity of 84.92% and a negative net margin of 16.35%. Sell-side analysts forecast that Ingevity Corporation will post 4.45 EPS for the current fiscal year.
Ingevity Profile
(
Free Report)
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.
See Also
Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
